(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 November 2020 (05.11.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/223351 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/30* (2006.01)
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2020/030478

(22) International Filing Date:
29 April 2020 (29.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/839,974 29 April 2019 (29.04.2019) US
62/860,598 12 June 2019 (12.06.2019) US

(71) Applicant: **IMMUNOGEN, INC.** [US/US]; 830 Winter Street, Waltham, Massachusetts 02451 (US).

(72) Inventors: **ADAMS, Sharlene**; 45 Rosemont Ave., Waltham, Massachusetts 02451 (US). **SLOSS, Callum M.**; 72 Greenwood Street, Wakefield, Massachusetts 01880 (US). **ZWEIDLER-MCKAY, Patrick**; 111 Old Country Road, Lincoln, Massachusetts 01773 (US).

(74) Agent: **STEFFE, Eric K.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES

(57) Abstract: Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.

WO 2020/223351 A1